Curanex Pharmaceuticals Inc Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CURX research report →
Price Chart
About the company
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne.
- CEO
- Jun Liu
- IPO
- 2025
- Employees
- 6
- HQ
- Jericho, NY, US
Get TickerSpark's AI analysis on CURX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.92M
- P/E
- -0.51
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 2.63
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -185.20%
- ROIC
- -402.66%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-4,239,076
- Net Income
- $-4,225,106-1068.8%
- EPS
- $-2.98-1046.2%
- OCF Growth
- -1787.1%
- FCF Growth
- -1787.1%
- 52W High
- $13.34
- 52W Low
- $3.58
- 50D MA
- $4.97
- 200D MA
- $6.07
- Beta
- -2.57
- RSI (14)
- 38
- Avg Volume
- 17.83K
No earnings-call transcripts are available for CURX yet.
- Free Float
- 26.6%
- Shares Outstanding
- 1.57M
- Float Shares
- 416.94K
of shares held by institutions
8 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 25, 25 | Xie Liqin | other | 0 |
| Aug 25, 25 | Hsu Helen Hong | other | 0 |
| Aug 25, 25 | Zhong Huijuan | other | 0 |
| Aug 25, 25 | Yan Yong | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Liu Jun | other | 0 |
| Aug 25, 25 | Hao Xiaohui | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CURX coverage
Recent articles, reports, and earnings notes.
No research on CURX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CURX report →Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
prnewswire.com · May 22
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
prnewswire.com · May 18
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
globenewswire.com · May 14
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
prnewswire.com · May 12
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm
globenewswire.com · Apr 30
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
businesswire.com · Apr 17
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
businesswire.com · Apr 16
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
globenewswire.com · Apr 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.